Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases

Andrea De Luca, David Clifford, David M Simpson, Gabriele Arendt, Gavin Giovannoni, Avindra Nath

Risultato della ricerca: Contributo in rivistaArticolo in rivista

515 Citazioni (Scopus)

Abstract

Background Treatment of multiple sclerosis with natalizumab is complicated by rare occurrence of progressive multifocal leukoencephalopathy (PML). Between July, 2006, and November, 2009, there were 28 cases of confi rmed PML in patients with multiple sclerosis treated with natalizumab. Assessment of these clinical cases will help to inform future therapeutic judgments and improve the outcomes for patients. Recent developments The risk of PML increases with duration of exposure to natalizumab over the fi rst 3 years of treatment. No new cases occurred during the fi rst two years of natalizumab marketing but, by the end of November, 2009, 28 cases had been confi rmed, of which eight were fatal. The median treatment duration to onset of symptoms was 25 months (range 6 80 months). The presenting symptoms most commonly included changes in cognition, personality, and motor performance, but several cases had seizures as the fi rst clinical event. Although PML has developed in patients without any previous use of disease-modifying therapies for multiple sclerosis, previous therapy with immunosuppressants might increase risk. Clinical diagnosis by use of MRI and detection of JC virus in the CSF was established in all but one case. Management of PML has routinely used plasma exchange (PLEX) or immunoabsorption to hasten clearance of natalizumab and shorten the period in which natalizumab remains active (usually several months). Exacerbation of symptoms and enlargement of lesions on MRI have occurred within a few days to a few weeks after PLEX, indicative of immune reconstitution infl ammatory syndrome (IRIS). This syndrome seems to be more common and more severe in patients with natalizumab-associated PML than it is in patients with HIV-associated PML. Where next? Diagnosis of natalizumab-associated PML requires optimised clinical vigilance, reliable and sensitive PCR testing of the JC virus, and broadened criteria for recognition of PML lesions by use of MRI, including contrast enhancement. Optimising the management of IRIS reactions will be needed to improve outcomes. Predictive markers for patients at risk for PML must be sought. It is crucial to monitor the risk incurred during use of natalizumab beyond 3 years.
Lingua originaleEnglish
pagine (da-a)438-446
Numero di pagine9
RivistaLANCET NEUROLOGY
Volume2010
Stato di pubblicazionePubblicato - 2010

Keywords

  • PML
  • natalizumab

Fingerprint Entra nei temi di ricerca di 'Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases'. Insieme formano una fingerprint unica.

Cita questo